HemoSonics, LLC

HemoSonics manufactures the Quantra® System, an FDA-cleared viscoelastic testing (VET) platform for real-time hemostasis assessment at the point of care. The Quantra System is the first and only viscoelastic testing platform FDA-cleared specifically for peripartum obstetric procedures, with additional FDA-cleared indications for cardiac surgery, trauma, liver transplantation, and major orthopedic surgery. The system delivers rapid, easy-to-interpret whole blood hemostasis data, enabling clinicians to make informed transfusion and hemostatic intervention decisions. Key product lines include QPlus® and QStat® Cartridges, which integrate with the Quantra analyzer. Clinical evidence demonstrates that viscoelastic testing reduces unnecessary blood product usage, length of hospital stay, transfusion-related complications, and time to hemostatic intervention. HemoSonics also offers External Quality Assessment (EQA) proficiency testing through partnership with sthemE Qualiris, providing comprehensive quality assurance for Quantra users. The company supports healthcare providers with implementation guidance, white papers on clinical and financial ROI, and educational resources. FDA 510(k) clearance and quality management system compliance underpin the product portfolio. The company targets hospital laboratories, operating rooms, and obstetric care teams seeking to optimize bleeding management protocols and reduce blood product consumption.